Celltrion’s Korean plant has received its second Form 483 from the FDA in less than a year, only months after having received a warning letter for the same facility.
Celltrion’s Korean plant has received its second Form 483 from the FDA in less than a year, only months after having received a warning letter for the same facility.
The heavily redacted form included 8 observations, including a lack of written procedures for production and process controls; a lack of training for employees processing a drug; no routine checks made of automatic equipment; and the failure to document the time and temperature of release, stability, and reference standard samples during transfer between freezers, among others.
In a statement, Celltrion said the citation contained “manageable and correctable inspection observations,” and that it expects outstanding observations to be lifted soon.
The citation is just the latest update in manufacturing woes for Celltrion that began in September 2017. Last year, Celltrion received the FDA’s Form 483 noting 12 inspection observations related to a range of issues including incomplete records, inappropriately designed equipment, deficient environmental monitoring, and inadequate validation of sterilization processes.
In February 2018, the company received a warning letter from the agency related to its manufacturing processes. Despite Celltrion’s assurance to investors that it would address the concerns in a timely manner, its partner Teva said that the remediation process would likely result in a “delayed approval” of jointly developed drugs.
Then, in April 2018, the company received Complete Response Letters for 2 of its products, CT-P10, a proposed rituximab biosimilar referencing Rituxan, and CT-P6, a proposed trastuzumab biosimilar referencing Herceptin. According to a statement on Celltrion’s website at the time, the FDA had requested supplementary information about the products. Celltrion also said that it would be working closely with the agency to address the issues, and that it still expects approvals for both products later this year.
Despite the manufacturing struggles faced at the South Korean plant, CT-P6 earned marketing authorization in the European Union (EU) in February of this year and is sold under the brand name Herzuma. Additionally, CT-P10 is also approved in the EU, where the therapy is marketed under the brand names Blitzima, Ritemvia, and Truxima.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.